Efficient Route to Label Mesenchymal Stromal Cell-Derived Extracellular Vesicles by Alberti, Diego et al.
Efficient Route to Label Mesenchymal Stromal Cell-Derived
Extracellular Vesicles
Diego Alberti,† Cristina Grange,‡ Stefano Porta,† Silvio Aime,† Lorenzo Tei,§
and Simonetta Geninatti Crich*,†
†Department of Molecular Biotechnology and Health Science, University of Turin, Via Nizza 52, 10126 Torino, Italy
‡Department of Medical Sciences, University of Turin, Corso Dogliotti 14, 10126 Torino, Italy
§Department of Science and Technological Innovation, University of Piemonte Orientale, Viale T. Michel 11, 15121 Alessandria,
Italy
*S Supporting Information
ABSTRACT: Recent research results report that extracellular
vesicles (EVs) have a central role in both physiological and
pathological processes involving intercellular communication.
Herein, a simple EVs labeling procedure based on the
metabolic labeling of secreting cells (mesenchymal stroma
cells, MSCs) with a fluorescein-containing bio-orthogonal dye
is described. This procedure was carried out by incubating
cells for 72 h with tetraacetylated N-azidoacetyl-D-mannos-
amine (Ac4ManNAz), a modified sugar containing an azido
group that, upon incorporation on the external surface of the
cytoplasmatic cell membrane, is specifically conjugated with
cyclooctyne-modified fluorescein isothiocyanate (ADIBO-
FITC). MSCs released fluorescent EVs did not need any
further purification. Finally, cellular uptake and tracking of the fluorescein-labeled EVs were successfully assessed by targeting
experiments with MSCs. The method appears of general applicability and it may be very useful opening new horizon on
diagnostic and therapeutic protocols exploiting EVs.
■ INTRODUCTION
It is now well established that extracellular vesicles (EVs) are a
powerful tool for intercellular communication.1 They consist of
a heterogeneous population of double layers membrane
fragments that are released by most cell types.2 EVs can
carry a payload made of molecules such as proteins, lipids, and
nucleic acids that are uptaken by target cells, influencing their
fate.3−6 In particular, a pro-regenerative ability has been
ascribed to EVs released by stem cells, that act by stimulating
recipient cell proliferation, inhibiting apoptosis, and favoring
immune escape.7−10 The use of stem cell derived EVs is
currently under intense scrutiny, as a novel putative therapeutic
option. In fact, it has been reported that EVs released by
mesenchymal stroma cells (MSCs) resulted highly efficient in
the treatment of several pathologies in preclinical experimental
models.11,12 A very promising characteristics of EVs relies in
their ability to transport genetic information, as well as drugs
and proteins, to target cells. In addition, EVs possess unique
properties including (i) enhanced passive targeting due to their
small size, (ii) excellent biological acceptance due to their
endogenous nature, and (iii) ability to cross biological barriers.
Their natural potential to transfer biological materials from one
cell to another can be enhanced or customized to enable a
wide range of therapeutic applications through the introduc-
tion of molecules that facilitate targeting, uptake, and loading
of EVs. To improve the use of MSC EVs, it is essential to track
EV biodistribution in vivo. Moreover, conjugation of imaging
probes to the surface of EVs that allows their not-invasive
detection is an important challenge. Currently, labeling
strategies used are based essentially on the use of highly
lipophilic fluorescent dyes, able to stain artificial and biological
membranes thanks to the presence of lipophilic long-chains
functionalized with cyanine moieties (i.e., PKH, DiD, DiI, and
R18).13−15 The aliphatic chain rapidly intercalates into the EVs
lipid bilayer, thus providing the fluorescent labeling of the
particles. Unfortunately, the protocols used to remove dye
aggregates nonbound to EVs lipidic membrane are often
insufficient, leading to the occurrence of many false positive
results.16,17 For these reasons, it appears useful to find
alternative, easy, and fast labeling procedures that avoid the
unspecific incorporation into the membrane of both EVs and
MSCs as in the case of lipophilic dyes. Herein, we report our
results on an EV labeling procedure with fluorescent dyes
based on the bio-orthogonal copper-free click chemistry
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approach. In recent years, the bio-orthogonal approach has
attracted considerable attention for cell labeling and/or
tracking because of its high specificity and low toxicity to
cells.18−20 Among the possible bio-orthogonal approaches, the
rapid, biocompatible, and specific chemical reaction between
the functionalized dibenzocyclooctyne and azido-sugars
generated on the cell surface by metabolic glycoengineering
has shown great potential.21−23 Thus, applying this approach,
cancer cells labeling strategies and targeted delivery of
nanoparticles have been recently developed and validated
also in vivo.24−28
Thus, first, the metabolic labeling of MSCs with
tetraacetylated N-azidoacetyl-D-mannosamine (Ac4ManNAz)
was carried out to generate unnatural azide groups on the
surface of the cells. This task was accomplished by growing
MSC cells in the presence of the modified sugar, and then the
azide groups specifically and efficiently reacted with fluorescein
conjugated aza-dibenzocyclooctyne (ADIBO-FITC) (Figure
1) via the Cu-free 1,3-dipolar cycloaddition reaction. A similar
bio-orthogonal approach has been very recently used by Lee et
al.29 to label exosomes isolated by breast cancer cells (MCF7
and MDA-MB-231) with a Cy3 fluorescent dye. However,
stem cells and MSCs used in this work possess completely
different characteristics compared with tumor cells, in terms of
metabolism, size, growth rate, and phenotypic markers. In
addition, MSCs may have different extent of extracellular
glycan formation with respect to tumor cells and different
amount of exosomes secreted.
■ RESULTS AND DISCUSSION
Mesenchymal Stroma Cells Labeling. To expose azide
groups on the surface of MSCs, the cells were incubated in the
presence of a solution of Ac4ManNAz (50 μM in 0.25 v/v %
ethanol in MSC basal medium) for 72 h at 37 °C (5% CO2).
Azide-modified sugars were incorporated through existing
biosynthetic pathways both onto the cell surface and on
internal glycans. After incorporation, the unnatural azide group
is available for reaction with the stable ADIBO-FITC (Figure
1). Thus, a further incubation of 30′ at 37 °C in the presence
of 40 μM ADIBO-FITC (0.2 v/v % ethanol in MSC basal
medium) was carried out to allow the Cu-free click chemistry
reaction to occur on cell surface. Then, after washing, the
fluorescent labeling on MSCs was assessed by flow cytometry.
As reported in Figure 2A, the fluorescence signal of MSCs
treated with Ac4ManNAz and ADIBO-FITC was much higher
with respect to control cells treated only with ADIBO-FITC,
confirming the successful labeling of the cells via the click
reaction. Different aliquots of the same cell samples were then
lysated and analyzed by spectrofluorimetry (Figure 2B). The
amount of FITC bound to MSCs was quantified based on a
FITC standard curve, and it was normalized to the total
protein content of cells determined by the Bradford method.
Figure 2B confirms the results obtained by fluorescence
activated cell sorting (FACS) analysis, thus evidencing the
Figure 1. Description of the bio-orthogonal labeling procedure of EVs.
Figure 2. Representative cytofluorimetric (A) and spectrofluorimetric
(B) analysis of MSCs labeled with ADIBO-FITC pre-incubated in the
presence or in the absence of Ac4ManNAz. Fluorescence values
measured on cell lysates (upon treatment with triton 0.1%) were
normalized to the total cell protein content determined by Bradford
assay. Data are the mean ± SE of seven different experiments. **p =
0.0024, Student t-test.
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absence of a nonspecific binding of ADIBO-FITC to the cell
cytosolic membrane in comparison with Ac4ManNAz-treated
cells. This clearly demonstrated that the amount of exposed
azide groups was sufficient to allow the detection of labeled
MSCs. No advantages were observed when different
concentrations of ADIBO-FITC (15 and 60 μM) were used
(Supporting Information Figure S1).
To assess whether MSC labeling was maintained over time,
cells previously treated with Ac4ManNAz and ADIBO-FITC
were kept in culture for additional 5 days. FACS analysis of
MSCs was performed at day 3 and day 5. Figure 3 shows that 5
days after cell labeling the fluorescence decreased of about 30%
according to the MSC growth rate. Importantly, the incubation
of MSCs with Ac4ManNAz and ADIBO-FITC did not affect
morphology and surface markers (Supporting Information
Figure S2) and showed a 70 ± 5% cells viability, measured by
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay, compared with not-treated control cells. In
addition, treatment with Ac4ManNAz and ADIBO-FITC did
not alter the MSCs endocytic pathway as demonstrated by
indirect immunofluorescence for specific molecules of different
endocytic compartments. Figure 4 shows that MSCs with
ADIBO-FITC with or without Ac4ManNAz have similar
distribution and intensity of EEA1, Rab 5, that localize in
early endosome, and they are involved in vesicle trafficking and
Lamp-1 a lysosomal marker. Moreover, MSCs treated or not
with Ac4ManNAz did not reveal significant changes of Tia-1
expression, that is, mRNA binding proteins that during stress
conditions localize into stress granules.
Labeled MSCs Released Fluorescent EVs. Cell super-
natants were collected from fluorescent MSCs (Ac4ManNAz
and ADIBO-FITC treated) cultured overnight in Roswell Park
Memorial Institute (RPMI) without serum, for EVs
purification. Labeled EVs were then obtained by ultra-
centrifugation. The advantage of the labeling protocol herein
proposed is that unbound dyes are eliminated directly during
MSC cells washing, and fluorescent exosomes are produced
directly by cells and do not need any further purification. On
the contrary, the procedure reported by Lee et al.29 was more
laborious and required a purification through a PD SpinTrap
G25 column. In particular, breast cancer cells (MCF7 and
MDA-MB-231) were metabolically labeled with Ac4ManNAz
and then exosomes were isolated by the cells and then labeled
with the ADIBO-fluorescent dye molecules (1 h at 37 °C), and
finally purified by gel filtration.
Labeled EVs were characterized by NanoSight analyses,
Guava cytofluorimeter, and spectrofluorimetric analysis. EVs’
number and size were quantified by nanoparticle tracking
analysis (NTA). As shown in Figure 5A, the size distribution
(nm) of EVs released by Ac4ManNAz and ADIBO-FITC
(165.5 ± 11 nm) or ADIBO-FITC (173 ± 7 nm) treated
MSCs was similar to the one of nonlabeled EVs (174 ± 2 nm),
demonstrating that the ADIBO-FITC exposure on the EV
membranes did not affect the EV size. Moreover, cytofluori-
metric analyses, performed using Guava cytofluorimeter, of
EVs released by Ac4ManNAz and ADIBO-FITC treated MSCs
and by cells treated only with ADIBO-FITC, did not show any
difference between the two EV types (Figure 5B). In particular,
both EVs expressed several exosomal markers (Figure 5B) such
as CD81, CD9, CD107, and CD63, known to be present on
EVs and some mesenchymal stromal cells markers as CD73,
CD44, and CD105, highly expressed on MSCs (Figure 5C).
Moreover, both EVs showed the presence of the adhesion
molecule CD29. It should be noted that MSC EVs enter into
target cells by a receptor-mediated mechanism through CD44
and CD29 molecules, as previously demonstrated by Camussi
et al.30 Therefore, the presence of these molecules at a
comparable level on EVs derived from Ac4ManNAz and
ADIBO-FITC-treated MSCs and from cells treated only with
ADIBO-FITC implies the retention of their excellent ability to
enter into target cells.
Figure 6A shows the fluorescence intensity of FITC analyzed
by Guava cytofluorimeter in unlabeled EVs derived from
nontreated MSCs (control) compared with EVs produced after
MSCs treatment with ADIBO-FITC or with Ac4ManNAz and
Figure 3. Representative cytofluorimetric analysis of fluorescence
maintenance by MSCs treated with Ac4ManNAz (50 μM) and
ADIBO-FITC (40 μM) at 0, 3, and 5 days post incubation.
Figure 4. Immunofluorescence analysis of endocytic markers (EEA1, Rab5, Lamp-1, and Tia-1) on MSCs treated with ADIBO-FITC with or
without Ac4ManNaz. Nuclei were stained with Hoechst (blue). Marker fluorescence (red) was evaluated using a Zeiss LSM 5 Pascal model
confocal microscope, magnification 63x.
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ADIBO-FITC. The last EVs population showed a higher
fluorescence intensity with respect to ADIBO-FITC-treated
EVs, thus demonstrating that the fluorescent dye introduced in
the parent cells by the bio-orthogonal approach translates to a
highly specific labeling of EVs. The level of different labeling of
EVs was then also assessed by spectrofluorimetric measure-
ments of their suspensions treated with triton 0.1% in
phosphate-buffered saline (PBS) (Figure 6B). It is important
to outline that the advantage of the herein proposed labeling
protocol relies on the fact that the separation of unbound
fluorescent dye occurs immediately after the cell incubation
step, thus avoiding to carry out the ultracentrifugation of EVs
in the presence of an excess of unbound dye. The unbound
dye, being often highly hydrophobic, can form aggregates that
can precipitate during the centrifugation step thus raising to an
unspecific fluorescence.
Tracking of Labeled EVs in MSCs Cells. Finally, to assess
whether the labeled EVs were still able to be uptaken into
target MSCs, a dedicated incorporation assay was performed.
Target cells were incubated for 1 h with EVs labeled as
described above. Then, the cells were washed and the presence
of fluorescent EVs within cells were evaluated by using a
fluorescence microscope. As reported in Figure 7, EVs were
clearly incorporated in the target cells generating a detectable
fluorescent signal, definitely more intense in the case of
Ac4ManNAz and ADIBO-FITC containing EVs thus confirm-
ing the validity of this labeling procedure based on the
exploitation of a bio-orthogonal reaction. In conclusion, in the
present study, a rapid, biocompatible, and specific chemical
reaction between the FITC-functionalized cyclooctyne and
azido-sugars, previously produced on the cell surface by
metabolic glycoengineering, has been exploited to produce
Figure 5. (A) Nanosight analysis. Representative size distribution of nonlabeled EVs (1), EVs derived from MCSs treated with ADIBO-FITC (2)
or both Ac4ManNAz and ADIBO-FITC (3). (B) Exosomal and (C) mesenchymal markers expressed on EVs labeled with ADIBO-FITC with or
without Ac4ManNAz.
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fluorescent exosomes. This approach aims at the development
of an advanced strategy for direct and clean EVs labeling. The
use of this labeling protocol can also be adapted to label EVs
surface with drugs or other imaging agents that can be
delivered to the pathological site, thanks to the specific
recruitment properties of these EVs. Moreover, this method
may allow the development of protocols for “in vivo” specific
labeling of target cells with Ac4ManNAz followed by ADIBO-
dye/drug administration and thus tracking biodistribution and
drug delivery.
■ EXPERIMENTAL PROCEDURES
All chemicals were purchased from Sigma-Aldrich or Alfa Aesar
unless otherwise stated and were used without further
purification.
The synthesis of Ac4ManNAz and ADIBO-FITC was carried
out following literature procedures.31 Briefly, Ac4ManNAz was
synthesized by 1-[3-(dimethylamino)propyl]-3-ethylcarbodii-
mide hydrochloride and N-hydroxybenzotriazole mediated
amidation of D-mannosamine hydrochloride with azidoacetic
acid in methanol in the presence of triethylamine, followed by
acetylation of the hydroxyl groups with acetic anhydride. Final
Ac4ManNAz was obtained after column chromatographic
purification in 90% overall yield.
ADIBO-C6-NH2 was synthesized starting from dibenzosu-
berenone by treatment with hydroxylamine to obtain
dibenzosuberenone-oxime that was then rearranged to lactam
by polyphosphoric acid-catalyzed Beckman rearrangement.
The lactam was then reduced with LiAlH4 to give
dihydrodibenzoazocine which was then acylated with 6-
(trifluoroacetamido)hexanoyl chloride. The alkyne was finally
obtained via a bromination-dehydrobromination procedure to
give the amino-functionalized aza-dibenzocyclooctyne
(ADIBO-C6-NH2) after saponification of the trifluoroaceta-
mide moiety with K2CO3 in aqueous methanol. The product
ADIBO-FITC was synthesized by treating ADIBO-C6-NH2
with equimolar amounts of fluorescein isothiocyanate in
dimethylformamide (DMF) in the presence of diisopropyle-
thylamine (DIPEA) and finally purified by column chromatog-
raphy.
Cell Labeling Experiments. Human bone marrow MSCs
were purchased from Lonza and cultured and as previously
described.32,33 MSCs derived from six preparations were used
up to the seven passages of culture. MSCs were grown in T75
flasks and when they reached 80% confluence, they were
incubated in the presence of 50 μM Ac4ManNAz (0.25 v/v %
ethanol in MSC basal medium, Lonza) for 72 h at 37 °C, 5%
CO2. After the incubation, they were washed three times with
PBS and incubated for further 30′ at 37 °C, 5% CO2 in the
absence or in the presence of 40 μM ADIBO-FITC (0.2 v/v %
ethanol in MSC basal medium). Then, the cells were washed
three times with PBS, detached with 1 mM EDTA,
resuspended in 250 μL of PBS and analyzed for their FITC
fluorescence and for mesenchymal stroma cell markers (CD
29, CD44, CD73, CD90, CD105, and CD146) by FACS.
FACS analyses were performed immediately (day 0) or after 3
or 5 days post labeling using a BD FASCalibur, (Franklin
Lakes, NY, USA); nontreated MSCs were used as control.
Aliquots of the samples analyzed by FACS were exploited for
total cell protein determination by the Bradford assay and
spectrofluorometric analysis. Samples were sonicated in ice at
30% power for 30 s and after proteins determination they were
diluted 1:10 in triton 0.1% in PBS and analyzed for their FITC
fluorescence according to a FITC calibration curve (ex 492 nm
em 517 nm in the range 0.5−30 nM). The obtained
nanomoles of FITC calculated for each cell samples were
normalized to milligrams of total cell proteins measured by
Bradford assays.
Immunofluorescence Experiment. Immunofluorescence
analysis of endocytic markers on MSCs treated with ADIBO-
FITC with or without Ac4ManNAz was performed on MSCs
cultured on glass wells. MSCs were fixed in 4% paraformalde-
hyde containing 2% sucrose and permeabilized with HEPES−
Figure 6. Representative cytofluorimetric (A) and spectrofluorimetric
(B) analysis of EVs released by unlabeled MSCs (gray), and by MSCs
labeled with ADIBO-FITC pre-incubated in the presence or in the
absence of Ac4ManNAz. Fluorescence values were normalized to the
total EVs protein content determined by the Bradford assay. Data are
the mean ± SE of three different experiments. **p = 0.0067, Student
t-test.
Figure 7. Fluorescent EVs internalization assay on MSCs. Cells were
incubated in the presence of EVs released by MSCs untreated (A,D),
treated with ADIBO-FITC (B,E) or Ac4ManNAz and ADIBO-FITC
(C,F). Nuclei were stained with DAPI (blue). FITC fluorescence
(green) was evaluated using an Apotome fluorescent microscope,
magnification 20× (A−C) and 40× (D−F).
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Triton X100 buffer (Sigma) immediately after the labeling
procedure. The following primary antibodies (Santa Cruz)
were used: EEA1 (sc-365652), Rab5 (sc-28570), Lamp-1 (sc-
8098), Tia-1(sc-1751). Omission of the primary antibodies
was used as control. Alexa Fluor 596 anti-rabbit, or anti-goat or
anti-mouse (Molecular Probes) were used as secondary
antibodies. Confocal microscopy analysis was performed
using a Zeiss LSM 5 Pascal model confocal microscope
(Carl Zeiss International). Hoechst 33258 dye (Sigma) was
added for nuclear staining.
MTT Assay. The MTT assay is based on the tetrazolium
salts reduction to formazan by mitochondrial succinate
dehydrogenase, which is quantified spectrophotometrically.
MSCs cells previously treated with 50 μM Ac4ManNAz for 72
h and 40 μM ADIBO-FITC for 30′ were seeded at a density of
3 × 103 cells/well in a 96-well microtiter plate at 37 °C and 5%
CO2 air atmosphere for 24 h. After this time, the medium was
removed and 100 μL of thiazolyl blue tetrazolium bromide
dissolved in medium at the concentration of 0.45 mg/mL was
added into each well and the plate was incubated for 4 h at 37
°C and 5% CO2. Then, the medium was removed, 150 μL of
dimethyl sulfoxide was added into each well to solubilize the
formazan salt crystals produced by the metabolism of live cells
and the microplate was incubated at room temperature for 30
min. Finally, absorbance was read at 570 nm with iMark
microplate reader (Biorad). Cell viability was reported as
percentage of death cells observed in treated samples relative
to that observed in not treated control cells. The experiment
was performed in triplicate, and the data were presented as
mean ± SD.
EVs Labeling Experiments. In agreement with the MSCs
labeling procedure described above, the EVs were produced
from MSCs cells pre-incubated with ADIBO-FITC in the
presence or in the absence of Ac4ManNAz. EVs were obtained
from supernatants of MSCs cultured overnight in RPMI
deprived of FCS. Cell supernatant was centrifuged at 3000g for
20 min to remove cell debris and apoptotic bodies and
subsequently was ultracentrifuged for 2 h at 100 000g
(Beckman Coulter) as previously described.30
EVs Quantification. EVs were analyzed by NTA, using the
NanoSight NS300 system (NanoSight Ltd, Amesbury, UK),
equipped with a 405 nm laser and a high sensitivity digital
camera system (OrcaFlash2.8, Hamamatsu C1 1440, Nano-
sight Ltd as previously described).33 For each sample, three
videos of 30 s duration were recorded. The settings of
acquisition and analysis were optimized and kept constant
between samples. The final analysis reports the mean, mode,
and median vesicle size and an estimation of the concentration.
EVs Cytofluorimetric Analysis. Cytofluorimetric analysis
was performed using a Guava easyCyte flow cytometer
(Millipore, Billerica, MA, USA) to detect EV fluorescence. In
addition, the following PE-conjugated antibodies were used to
characterize EV surface markers: anti-CD81, anti-CD9, anti-
CD107, anti-CD63, anti-CD73, anti-CD44, anti-CD105, and
anti CD29 (all from Becton Dickinson). All experiments were
analyzed with InCyte software.
EVs Spectrofluorometric Analysis. EVs were lysated in
the presence of triton 0.1% in PBS and analyzed by
spectrofluorimetry (HORIBA Jobin Yvon Fluoromax-4 spec-
trofluorometer, Edison, NY, USA). The nanomoles of FITC
calculated for each EV samples were normalized to mg of total
EVs proteins previously determined by the Bradford assay. EVs
derived from not treated MSCs were used as control in all the
performed studies.
Uptake of FITC-Labeled EVs on Target Cells. MSCs
were cultured onto glass dishes and when they reached 80%
confluence, they were incubated in the presence of 20 000
FITC-labeled EVs/cell produced from MSCs pre-incubated
with ADIBO-FITC in the presence or in the absence of
Ac4ManNAz. After 1 h of incubation at 37 °C 5% CO2, the
cells were extensively washed with PBS, they were fixed in PAF
and nuclei were stained with DAPI (Sigma). Cells fluorescence
was evaluated using an Apotome fluorescent microscope
(Zeiss), magnification 20× and 40×.
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